Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF) announced management will participate in two investor conferences in November 2025. CEO Mark Erlander, PhD will appear at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on 11/11/2025 at 9:30 AM ET for a fireside chat and 1x1 meetings, and at the Stifel 2025 Healthcare Conference on 11/12/2025 at 9:20 AM ET for a corporate presentation and 1x1 meetings.

Interested parties can register and access live webcasts via the company’s Events page; replay will be available after each presentation.

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in November 2025.

Guggenheim Securities 2^nd Annual Healthcare Innovation Conference
Format: Fireside Chat and 1x1 Meetings
Presenters: Mark Erlander, PhD (CEO)
Date: 11/11/2025
Time: 9:30 AM ET

Stifel 2025 Healthcare Conference
Format: Corporate Presentation and 1x1 Meetings
Presenters: Mark Erlander, PhD (CEO)
Date: 11/12/2025
Time: 9:20 AM ET

Interested parties can register for and access the live webcast for the conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com

Investor Contact:
Candice Masse
Astr Partners
candice.masse@astrpartners.com

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

FAQ

When will Cardiff Oncology (CRDF) present at the Guggenheim Healthcare Innovation Conference?

Cardiff Oncology will present on 11/11/2025 at 9:30 AM ET in a fireside chat format with 1x1 meetings.

What is the date and time for Cardiff Oncology's presentation at the Stifel 2025 Healthcare Conference (CRDF)?

The presentation is scheduled for 11/12/2025 at 9:20 AM ET as a corporate presentation with 1x1 meetings.

Who will represent Cardiff Oncology (CRDF) at the November 2025 investor conferences?

CEO Mark Erlander, PhD is listed as the presenter for both conference appearances.

How can investors watch the Cardiff Oncology (CRDF) conference presentations live?

Investors can register for and access the live webcasts via the company’s Events page on its website.

Will Cardiff Oncology (CRDF) make the conference presentations available after the events?

Yes, the webcast replay will be available after each presentation concludes on the company website.

What formats will Cardiff Oncology (CRDF) use at the November 2025 conferences?

At Guggenheim the format is a fireside chat and 1x1 meetings; at Stifel it is a corporate presentation and 1x1 meetings.